The trial tested adjuvant intravesical cretostimogene grenadenorepvec against a control arm in certain patients with non-muscle invasive bladder cancer following complete tumor resection. CG Oncology described the improvements as statistically significant and clinically meaningful.
The company said the treatment was generally well tolerated, with safety results consistent with those in previous studies. No treatment-related adverse events of grade 3 or greater were reported, according to CG Oncology.

Comments (0)
No comments yet. Be the first!